rs770946823

Variant summary

Our verdict is Likely benign. The variant received -2 ACMG points: 0P and 2B. BP4BP6

The NM_001387283.1(SMARCA4):​c.979C>A​(p.Pro327Thr) variant causes a missense change. The variant allele was found at a frequency of 0.00000937 in 1,600,088 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. P327A) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.000013 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0000090 ( 0 hom. )

Consequence

SMARCA4
NM_001387283.1 missense

Scores

1
11
7

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:2B:1

Conservation

PhyloP100: 4.79

Publications

1 publications found
Variant links:
Genes affected
SMARCA4 (HGNC:11100): (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4) The protein encoded by this gene is a member of the SWI/SNF family of proteins and is similar to the brahma protein of Drosophila. Members of this family have helicase and ATPase activities and are thought to regulate transcription of certain genes by altering the chromatin structure around those genes. The encoded protein is part of the large ATP-dependent chromatin remodeling complex SNF/SWI, which is required for transcriptional activation of genes normally repressed by chromatin. In addition, this protein can bind BRCA1, as well as regulate the expression of the tumorigenic protein CD44. Mutations in this gene cause rhabdoid tumor predisposition syndrome type 2. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2012]
SMARCA4 Gene-Disease associations (from GenCC):
  • Coffin-Siris syndrome
    Inheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet, Illumina
  • intellectual disability, autosomal dominant 16
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae), Ambry Genetics
  • rhabdoid tumor predisposition syndrome 2
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, ClinGen, Genomics England PanelApp, Labcorp Genetics (formerly Invitae), G2P
  • uterine corpus sarcoma
    Inheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
  • familial rhabdoid tumor
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • hereditary nonpolyposis colon cancer
    Inheritance: AD Classification: LIMITED Submitted by: ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Likely_benign. The variant received -2 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.3555234).
BP6
Variant 19-10987785-C-A is Benign according to our data. Variant chr19-10987785-C-A is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 238534.We mark this variant Likely_benign, oryginal submission is: [Conflicting_classifications_of_pathogenicity].

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
SMARCA4NM_001387283.1 linkc.979C>A p.Pro327Thr missense_variant Exon 6 of 36 ENST00000646693.2 NP_001374212.1
SMARCA4NM_003072.5 linkc.979C>A p.Pro327Thr missense_variant Exon 6 of 35 ENST00000344626.10 NP_003063.2 P51532-1A7E2E1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
SMARCA4ENST00000646693.2 linkc.979C>A p.Pro327Thr missense_variant Exon 6 of 36 NM_001387283.1 ENSP00000495368.1 Q9HBD4
SMARCA4ENST00000344626.10 linkc.979C>A p.Pro327Thr missense_variant Exon 6 of 35 1 NM_003072.5 ENSP00000343896.4 P51532-1
SMARCA4ENST00000643549.1 linkc.979C>A p.Pro327Thr missense_variant Exon 6 of 35 ENSP00000493975.1 A0A2R8Y4P4
SMARCA4ENST00000541122.6 linkc.979C>A p.Pro327Thr missense_variant Exon 7 of 35 5 ENSP00000445036.2 P51532-4
SMARCA4ENST00000643296.1 linkc.979C>A p.Pro327Thr missense_variant Exon 6 of 34 ENSP00000496635.1 P51532-4
SMARCA4ENST00000644737.1 linkc.979C>A p.Pro327Thr missense_variant Exon 6 of 34 ENSP00000495548.1 P51532-4
SMARCA4ENST00000589677.5 linkc.979C>A p.Pro327Thr missense_variant Exon 7 of 35 5 ENSP00000464778.1 P51532-3
SMARCA4ENST00000643995.1 linkc.391C>A p.Pro131Thr missense_variant Exon 3 of 32 ENSP00000496004.1 A0A2R8YGG3

Frequencies

GnomAD3 genomes
AF:
0.0000132
AC:
2
AN:
152078
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000294
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.00000941
AC:
2
AN:
212608
AF XY:
0.0000171
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.0000311
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000110
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.00000898
AC:
13
AN:
1448010
Hom.:
0
Cov.:
34
AF XY:
0.0000125
AC XY:
9
AN XY:
719334
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
33154
American (AMR)
AF:
0.0000231
AC:
1
AN:
43222
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
25766
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39004
South Asian (SAS)
AF:
0.00
AC:
0
AN:
84838
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
50472
Middle Eastern (MID)
AF:
0.000177
AC:
1
AN:
5638
European-Non Finnish (NFE)
AF:
0.00000904
AC:
10
AN:
1106202
Other (OTH)
AF:
0.0000167
AC:
1
AN:
59714
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.521
Heterozygous variant carriers
0
1
2
2
3
4
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0000132
AC:
2
AN:
152078
Hom.:
0
Cov.:
32
AF XY:
0.00
AC XY:
0
AN XY:
74284
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
41412
American (AMR)
AF:
0.00
AC:
0
AN:
15256
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3470
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5192
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4828
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10610
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
316
European-Non Finnish (NFE)
AF:
0.0000294
AC:
2
AN:
67994
Other (OTH)
AF:
0.00
AC:
0
AN:
2088
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.600
Heterozygous variant carriers
0
0
1
1
2
2
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00
Hom.:
0
Bravo
AF:
0.00000378
ExAC
AF:
0.0000169
AC:
2

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:2Benign:1
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

Intellectual disability, autosomal dominant 16 Uncertain:1
Jul 15, 2021
Genome-Nilou Lab
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Rhabdoid tumor predisposition syndrome 2 Uncertain:1
Aug 29, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change replaces proline, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 327 of the SMARCA4 protein (p.Pro327Thr). This variant is present in population databases (rs770946823, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with SMARCA4-related conditions. ClinVar contains an entry for this variant (Variation ID: 238534). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed for this missense variant. However, the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on SMARCA4 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -

Hereditary cancer-predisposing syndrome Benign:1
Dec 10, 2021
Ambry Genetics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
0.38
BayesDel_addAF
Uncertain
0.032
T
BayesDel_noAF
Benign
-0.090
CADD
Uncertain
24
DANN
Uncertain
1.0
DEOGEN2
Uncertain
0.67
D;.;T;.;.;.;.;.;.;.;D;.;.;.;.;.;T;T
Eigen
Uncertain
0.23
Eigen_PC
Uncertain
0.23
FATHMM_MKL
Uncertain
0.90
D
LIST_S2
Uncertain
0.93
.;D;.;.;.;.;D;.;.;.;D;.;D;D;D;D;D;D
M_CAP
Pathogenic
0.33
D
MetaRNN
Benign
0.36
T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T
MetaSVM
Uncertain
0.45
D
MutationAssessor
Benign
1.7
L;.;.;.;L;L;.;L;L;L;L;L;L;L;L;L;.;.
PhyloP100
4.8
PrimateAI
Uncertain
0.77
T
PROVEAN
Benign
-2.3
N;.;.;.;.;.;.;.;.;.;N;.;N;.;N;.;N;N
REVEL
Uncertain
0.49
Sift
Benign
0.075
T;.;.;.;.;.;.;.;.;.;T;.;T;.;T;.;T;T
Sift4G
Benign
0.18
T;.;.;.;.;.;.;.;.;.;T;.;T;T;T;T;T;T
Polyphen
0.90
P;.;P;.;.;.;.;.;.;.;P;.;.;.;.;.;.;P
Vest4
0.36
MutPred
0.29
Loss of catalytic residue at P327 (P = 0.0318);Loss of catalytic residue at P327 (P = 0.0318);Loss of catalytic residue at P327 (P = 0.0318);Loss of catalytic residue at P327 (P = 0.0318);Loss of catalytic residue at P327 (P = 0.0318);Loss of catalytic residue at P327 (P = 0.0318);Loss of catalytic residue at P327 (P = 0.0318);Loss of catalytic residue at P327 (P = 0.0318);Loss of catalytic residue at P327 (P = 0.0318);Loss of catalytic residue at P327 (P = 0.0318);Loss of catalytic residue at P327 (P = 0.0318);Loss of catalytic residue at P327 (P = 0.0318);Loss of catalytic residue at P327 (P = 0.0318);Loss of catalytic residue at P327 (P = 0.0318);Loss of catalytic residue at P327 (P = 0.0318);Loss of catalytic residue at P327 (P = 0.0318);Loss of catalytic residue at P327 (P = 0.0318);Loss of catalytic residue at P327 (P = 0.0318);
MVP
0.67
MPC
0.29
ClinPred
0.53
D
GERP RS
4.3
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
Varity_R
0.17
gMVP
0.31
Mutation Taster
=28/72
disease causing

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs770946823; hg19: chr19-11098461; API